Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.795 USD | -0.09% | -6.08% | +29.93% |
Financials (USD)
Sales 2024 * | 66.97M | Sales 2025 * | 78.82M | Capitalization | 898M |
---|---|---|---|---|---|
Net income 2024 * | -152M | Net income 2025 * | -129M | EV / Sales 2024 * | 13.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.4 x |
P/E ratio 2024 * |
-5.39
x | P/E ratio 2025 * |
-6.62
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.29% |
Latest transcript on Ocular Therapeutix, Inc.
1 day | -0.09% | ||
1 week | -6.08% | ||
Current month | +22.26% | ||
1 month | +24.76% | ||
3 months | -41.23% | ||
6 months | +158.71% | ||
Current year | +29.93% |
Managers | Title | Age | Since |
---|---|---|---|
Donald Notman
DFI | Director of Finance/CFO | 64 | 17-09-24 |
Chief Tech/Sci/R&D Officer | - | 21-09-27 | |
Jeffrey S. Heier
CTO | Chief Tech/Sci/R&D Officer | 63 | 15-09-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Adrienne Graves
BRD | Director/Board Member | 69 | 23-07-09 |
Director/Board Member | 76 | 12-11-04 | |
Merilee Raines
BRD | Director/Board Member | 68 | 21-09-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 1,487 M€ | +8.80% | - | |
0.00% | 9 M€ | +10.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 5.795 | -0.09% | 1,277,079 |
24-05-23 | 5.8 | -3.33% | 1,594,550 |
24-05-22 | 6 | -1.64% | 1,005,738 |
24-05-21 | 6.1 | -3.02% | 1,534,579 |
24-05-20 | 6.29 | +1.94% | 1,815,334 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.93% | 898M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- OCUL Stock